Earendil Labs has raised USD 787 million in financing rounds. The investment included participation by a group of global investors, including Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi and Biotech Development Fund (created by Hillhouse and Pfizer), alongside other existing and new technology and healthcare-focused investors.

With this funding, the company plans to scale its Artificial Intelligence (AI)-driven research and development across biologics discovery and development while expanding its scientific, engineering, and translational teams to support pipeline growth. The capital will also advance multiple internal programmes towards clinical milestones and deepen strategic partnerships to accelerate the delivery of innovative biologics to patients globally.

The funding will accelerate Earendil Labs' AI-driven R&D platform, expand its inter-disciplinary teams, and advance a growing pipeline of antibody and biologics programmes, with the goal of delivering first-in-class and best-in-class therapies for patients with serious diseases.

"AI is at the core of everything we do — not as a research tool, but as a production engine for real therapeutic programmes. This financing allows us to operate at a fundamentally different scale, advancing multiple programmes towards the clinic while building an R&D organisation designed for long-term impact," said Jian Peng, PhD, Founder and CEO, Earendil Labs.

Earendil Labs integrates AI across the full life cycle of biologics R&D, enabling the systematic generation and progression of differentiated therapeutic programmes. The company's AI-native platform has produced over 40 programmes, including HXN-1001, a half-life extended anti-TL1A antibody which is ready for phase-II clinical development, together with multiple IND submissions planned in 2026 and 2027.

"Our focus is ultimately on patients suffering from diseases that still lack effective treatment options. This funding greatly strengthens our ability to translate AI-enabled innovation into potentially transformative medicines and provides opportunities to partner with global leaders to accelerate our research and development programmes worldwide," said Zhenping Zhu, MD, PhD, Co-Founder, President and Co-CEO, Earendil Labs.

The platform's productivity and R&D execution are further validated through strategic collaborations with Sanofi. In 2025, Earendil Labs announced a worldwide exclusive licence agreement with Sanofi for next-generation bispecific antibodies for autoimmune and inflammatory bowel diseases, covering HXN-1002 and HXN-1003. More recently, Earendil Labs and Sanofi entered a broader strategic collaboration to apply its AI-driven discovery platform to multiple autoimmune and inflammatory disease programmes.

"Earendil Labs stands out for its ability to translate AI innovation into real, scalable R&D execution. The team has shown that AI can consistently generate high-quality biologics programmes and advance them towards the clinic. We are excited to support Earendil Labs as it builds a new paradigm for biologics discovery and development," said Zavain Dar, Founding Managing Partner, Dimension Capital.